Phase II Study of the Efficacy of the Pneumococcal Pneumonia Vaccine Series in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency (PROTECT CLL)
Latest Information Update: 26 Feb 2025
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal 23-valent vaccine Walvax Biotechnology (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Acronyms PROTECT CLL
Most Recent Events
- 21 Feb 2025 Planned End Date changed from 7 Jan 2027 to 7 Jan 2028.
- 21 Feb 2025 Planned primary completion date changed from 7 Jan 2025 to 7 Jan 2026.
- 14 Jan 2022 Status changed from not yet recruiting to recruiting.